Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought... Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Mehr anzeigen
TRYNGOLZA™ (olezarsen) approved in U.S. as first-ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet PR Newswire CARLSBAD, Calif., Dec. 19, 2024...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1 | -2.78396436526 | 35.92 | 36.96 | 34.85 | 924541 | 35.79132377 | CS |
| 4 | -0.83 | -2.32167832168 | 35.75 | 40.1 | 34.85 | 1591416 | 36.80258265 | CS |
| 12 | -2.91 | -7.69230769231 | 37.83 | 40.58 | 33.33 | 1429945 | 37.00678201 | CS |
| 26 | -12.85 | -26.8997278627 | 47.77 | 52.34 | 33.33 | 1507395 | 41.49088466 | CS |
| 52 | -16.49 | -32.0754716981 | 51.41 | 54.4446 | 33.33 | 1351064 | 42.7716024 | CS |
| 156 | 4.38 | 14.3418467583 | 30.54 | 54.4446 | 28.25 | 1158724 | 41.12911631 | CS |
| 260 | -24.99 | -41.7125688533 | 59.91 | 64.37 | 25.04 | 1129698 | 42.99256731 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
